Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT06712472
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The RAINBO program is a studies group which proposes personalized treatment of patients suffering from endometrial cancer according to their molecular profile. the RAINBO-RED study allows observation or maintenance treatment with targeted therapy for one year (olaparib). This after standard therapy. The goal is to improve recurrence-free survival of patients treated with Olaparib.

Key Dates

Start date
Jun 26, 2024
Status verified
Jan 2026
Primary completion
Jun 30, 2030
Completion
Dec 31, 2031

Study Design

Enrollment
554 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Standard arm
  • Experimental: Experimental arm

Primary Outcome Measure

Recurrence-Free survival [ Time Frame: 3 years ]

Central Contacts

Related Studies